Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Premal Lulla

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Cytotherapy|May 31, 2024
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumorsAnne Miller, Rachel Daum, Tao Wang, et al.
Haematologica|November 14, 2022
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patientsSpyridoula Vasileiou, LaQuisa Hill, Manik Kuvalekar, et al.
Blood|December 25, 2023
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomasLaQuisa C Hill, Rayne H Rouce, Mengfen J Wu, et al.
Blood Advances|October 21, 2021
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysisMehdi Hamadani, Ajay K Gopal, Marcelo Pasquini, et al.
Bone Marrow Transplantation|February 2, 2022
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphomaBrian D Friend, Ibrahim N Muhsen, Shreeya Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2017
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell TransplantationIfigeneia Tzannou, Anastasia Papadopoulou, Swati Naik, et al.
Therapeutic Advances in Medical Oncology|July 21, 2022
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancerValentina Hoyos, Spyridoula Vasileiou, Manik Kuvalekar, et al.
Research Square|April 22, 2024
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Nature|November 28, 2024
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Blood Advances|October 29, 2024
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell diseaseMark C Walters, Mary Eapen, Yiwen Liu, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Cytotherapy|May 31, 2024
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumorsAnne Miller, Rachel Daum, Tao Wang, et al.
Haematologica|November 14, 2022
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patientsSpyridoula Vasileiou, LaQuisa Hill, Manik Kuvalekar, et al.
Blood|December 25, 2023
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomasLaQuisa C Hill, Rayne H Rouce, Mengfen J Wu, et al.
Blood Advances|October 21, 2021
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysisMehdi Hamadani, Ajay K Gopal, Marcelo Pasquini, et al.
Bone Marrow Transplantation|February 2, 2022
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphomaBrian D Friend, Ibrahim N Muhsen, Shreeya Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2017
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell TransplantationIfigeneia Tzannou, Anastasia Papadopoulou, Swati Naik, et al.
Therapeutic Advances in Medical Oncology|July 21, 2022
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancerValentina Hoyos, Spyridoula Vasileiou, Manik Kuvalekar, et al.
Research Square|April 22, 2024
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Nature|November 28, 2024
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Blood Advances|October 29, 2024
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell diseaseMark C Walters, Mary Eapen, Yiwen Liu, et al.
Pageof 4